Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2018
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms GOLDEN-2
- Sponsors Sunovion Respiratory Development
- 24 May 2017 Results from GOLDEN 2 and GOLDEN 6 trials presented at the 113th International Conference of the American Thoracic Society
- 27 Oct 2014 Primary endpoint has been met (Change from baseline in morning trough FEV1) according to abstract presented at the 2014 American college of Chest Physicians Annual meeting.
- 27 Oct 2014 Results published at the 2014 American college of Chest Physicians Annual meeting.